[Hot spot]

Changshan Pharmaceuticals: No clinical trials of Ebenatide for obesity or weight loss have been conducted

Changshan Pharmaceutical (300255) issued a change announcement on the evening of September 24, stating that the company's current clinical trials of Ebenatide are for the treatment of type 2 diabetes and do not involve obesity indications. The Company has not conducted clinical trials of exbenatide for obesity or weight loss.

Jihong shares: net profit in the first three quarters increased by 58.3-62.5 year on year

Jihong shares (002803) released a performance forecast on the evening of September 24. The first three quarters are expected to achieve a net profit of 0.315 billion -0.323 billion yuan, an increase of 58.3-62.5 over the same period last year. During the reporting period, the consumer market in the RCEP agreement area, the main sales area of the company's cross-border e-commerce business, continued the recovery trend, the purchasing power of consumers further increased, and the revenue scale and profit of the company's cross-border e-commerce business increased significantly.

Xiamen Tungsten: Signed Cooperation Framework Agreement with China Rare Earth Group

Xiamen Tungsten (600549) announced on the evening of September 24 that on September 23, the company signed a "Cooperation Framework Agreement" with China Rare Earth Group Co., Ltd. In order to promote the high-quality development of the rare earth industry in Fujian Province, the two sides intend to carry out extensive cooperation in the fields of Fujian rare earth mining development, Fujian rare earth smelting and separation industry, raw material guarantee for Fujian rare earth deep processing industry, rare earth industry fund and innovation. The two sides plan to set up two joint ventures, with China Rare Earth Group holding 51% and Xiamen Tungsten (or a holding subsidiary of Xiamen Tungsten) holding 49% to jointly operate rare earth mines and rare earth smelting and separation industries controlled by Xiamen Tungsten (including the controlling shareholder of Xiamen Tungsten and the holding subsidiary of Xiamen Tungsten). After that, strive to further expand the scale of mining and smelting separation scale.

Huayou Cobalt: Memorandum of Understanding with LG Chem

huayou cobalt industry (603799) announced on the evening of September 24. on September 22, the company signed a memorandum of understanding with LG chemical. The memorandum stipulates that LG Chemical and the company will establish a strategic cooperative relationship in the overall value chain of precursor and cathode materials, and the two sides plan to set up a joint venture in Indonesia for high-pressure acid leaching wet smelting, refining and precursor, and a joint venture in Morocco for lithium salt processing.

Guocheng Mining: filed by CSRC for suspected violation of letter disclosure

Guocheng Mining (000688) announced on the evening of September 24 that the China Securities Regulatory Commission decided to file a case against the company for suspected violations of information disclosure. In addition, Jinxin Mining, a subsidiary of the company, received a notice from the Malkang Emergency Management Bureau on September 23. After on-site verification, Jinxin Mining has met the conditions for resuming work and production, and agreed to resume work and production.

Rongfa Nuclear Power: subsidiary Deyang Wanda was removed from the list of dishonest enforcers

Rongfa Nuclear Power (002366) announced on the evening of September 24 that due to the influence of previous litigation matters, Deyang Wanda, a wholly-owned subsidiary of the company, was included in the list of untrustworthy persons subject to enforcement. Now the contract dispute of Deyang Wanda has been properly resolved. After inquiry, Deyang Wanda has been removed from the list of untrustworthy persons subject to enforcement.

Sichuan road and bridge: property losses of JN1 bid section of riverside expressway project are still under statistics

Sichuan Road and Bridge (600039) disclosed on the evening of September 24 the progress of the "8 · 21" mountain torrent disaster disposal of the JN1 bid section of the Yanjiang Expressway: Up to now, the company has carried out the aftermath of the disaster-stricken families in an orderly manner and simultaneously promoted insurance claims. Actively cooperate with relevant departments to conduct investigations. At the same time, the company has comprehensively organized the investigation and rectification of potential safety hazards to ensure the steady progress of production in each project. The contract amount of JN1 bid section of Yanjiang Expressway is about 1.6 billion yuan, accounting for a small proportion of the total revenue of Luqiao Group, a wholly-owned subsidiary of the company. The specific property damage caused by the disaster is still in the statistics, to be further verified. The JN1 section of the highway along the river is currently in a state of shutdown, the follow-up will be in accordance with the provisions of the orderly resumption of work. In the early morning of August 21, a flash flood broke out in Jinyang County, Liangshan Prefecture, involving the damage to the JN1 (Jinning I) bid section of the riverside expressway constructed by the Road and Bridge Group. The plank house of the migrant worker's residence in the steel bar processing plant, the subcontracting unit of the bid section project, was washed away. At the time of the disaster, there were 201 people on the project site, of which 149 were out of danger, 4 were killed and 48 were lost.

blonde rabbi: the suspension of production and rectification of subordinate cosmetics factories will not have a significant impact

Blonde Rabbi (002762) announced on the evening of September 24 that the joint inspection team of the State Food and Drug Administration and the Guangdong Food and Drug Administration conducted an on-site inspection of the cosmetics factory under the company from August 16 to 17. It was found that the production management did not conform to the "Cosmetic Production Quality Management Standard" and "Cosmetic Production Quality Management Standard Inspection Points" and other related problems need to be rectified. On September 22, after the State Food and Drug Administration issued a notice, the company's cosmetics factory immediately stopped production and actively continued to rectify as required. In the near future, it will apply for a review by the drug administration department to resume production as soon as possible. The incident involves the company's cosmetics category, with operating income of about 25.1893 million yuan in 2022, accounting for 10.27 of the company's operating income in 2022. The incident does not have a significant impact on the company's daily production and operation.

Kyushu Tong: Application for Issuance of Preferred Shares to Specific Objects Approved by SSE

Kyushu Tong (600998) announced on the evening of September 24 that the company's application for issuing preferred shares to specific objects was approved by the Shanghai Stock Exchange.

[the winning contract]

runjian shares: pre-bid for 0.122 billion yuan China tower comprehensive maintenance service procurement project

runjian shares (002929) announced on the evening of September 24 that the online business platform of China tower recently released the "announcement of successful candidates for the comprehensive maintenance service procurement project 2023-2026 of Jiangsu branch of China tower co., ltd." the company is the successful candidate for the above-mentioned project, and the total bid scale for the whole service cycle is 0.122 billion yuan (including tax).

Longquan shares: pre-bid for 62.06 million yuan stainless steel pipe fittings and equipment procurement project

Longquan shares (002671) announced on the evening of September 24 that Xinfeng pipe industry, a wholly-owned subsidiary, was identified as the first candidate for "Zhangzhou 34, Sanmen 56, Jindian project, Jiangsu green energy project RCC-M1, grade 2 and grade 3 stainless steel pipe fittings and equipment procurement bid (II). The bid price is 62.0616 million yuan, accounting for about 6.23 of the company's operating income in 2022.

[Other]

Saiyi Information: Subsidiary Company Plans to Acquire 100 Equity of Sinobo for 0.211 billion Yuan

Saiyi Information (300687) announced on the evening of September 24 that Shanghai Saiyi, a wholly-owned subsidiary, plans to acquire a 100 percent stake in Beijing Sinobo Information Technology Co., Ltd. (hereinafter referred to as "Sinobo") for 0.211 billion yuan. The core team of Snoop or its designated agent will purchase the shares of Saiyi Information in two batches with an after-tax equity transfer price of not less than 0.11 billion yuan. The development of this transaction will help to further improve the company's business layout in the country, especially in the northern region; further increase the company's market share in the digital construction of central enterprises and group enterprises with great development potential and strong momentum.

Sentai shares: to set up an overseas holding subsidiary to build a new production base in Thailand

Sentai shares (301429) announced on the evening of September 24 that the company intends to set up a holding subsidiary in Thailand to purchase land, build new factories, purchase machinery and equipment, and build production bases. The planned investment amount of the project shall not exceed 0.35 billion yuan.

Gaole shares: proposed to set up a wholly-owned subsidiary in Shanghai to seek new profit growth point

Gaole shares (002348) announced on the evening of September 24 that in order to further optimize the business layout and seek new profit growth points for the company, the company plans to use 10 million yuan to invest in Shanghai to set up a wholly-owned subsidiary, Shanghai Gaole Shenhui Technology Development Co., Ltd.

nawei technology: plans to increase capital by 18 million yuan

nawei technology (688690) announced on the evening of September 24 that the company plans to increase the capital of Suzhou xinduo electronic technology co., ltd. (hereinafter referred to as "xinduo electronic") with five other investors, with a total capital increase of 55 million yuan, of which the company plans to increase the capital of 18 million yuan to xinduo electronic. after the capital increase, the company holds a total of 33.73 equity of xinduo electronic, and xinduo electronic is still the company. Xin Dao Electronics is mainly engaged in the research and development, production and sales of anisotropic conductive adhesive film (referred to as "ACF"). ACF conductive adhesive film is the key material to connect the chip and panel, and the company's conductive gold ball and other microsphere products are an important part of ACF conductive adhesive film, the company's first investment in 2019, the purpose is to promote the company's microsphere products to extend to the downstream industry chain, expand market development space.

Changhua Chemical: plans to use part of the over-raised funds to expand the polymer polyol project

Changhua chemical (301518) announced on the evening of September 24 that it plans to use some of the over-raised funds of 80 million yuan to pay for the remaining investment funds for the expansion of the 180000-ton/year polymer polyol project. The total investment of the project is expected to be 0.265 billion yuan. Up to now, the project has completed the main construction of the project and the installation and commissioning of equipment. The trial production plan has been reviewed and approved by the expert group and has entered the trial production stage.

east China heavy machinery: re-public listing and transfer of 100% equity of runxing technology

Huadong Heavy Machinery (002685) announced on the evening of September 24 that the company received a notice from the Shenzhen United Property Rights Exchange that within 10 working days of the public listing period, it failed to solicit eligible intended transferee. The company plans to reduce the listing price by 15% on the basis of the initial listing reserve price of 0.937 billion yuan, that is, to re-list and transfer 100% of the shares of Runxing Technology at the price of 0.797 billion yuan. Up to now, more than 5% of the company's shareholders Zhou Wenyuan has informed the company of its intention to participate in the acquisition of 100 of Runxing Technology when the conditions are appropriate.

yimikang: to transfer 53.84% equity of Jiangsu yijin, a holding subsidiary

yimikang (300249) announced on the evening of September 24 that based on the strategic consideration of focusing on the field of information and data, the company divested the environmental protection industry that could not form synergy with the field of information and data, and proposed to transfer 53.84% equity of its holding subsidiary Jiangsu yijin environmental protection technology co., ltd. (hereinafter referred to as "Jiangsu yijin") for 30 million yuan, with the transferee being Jiangsu beiji environmental technology co. According to preliminary estimates, the investment income is expected to be -57.47 million yuan when the transaction is completed within 2023, which will have a significant impact on the company's operating results in 2023.

yuandong biology: subsidiary shuode pharmaceutical passed FDA on-site inspection

yuandong biology (688513) announced on the evening of September 24 that Chengdu shuode pharmaceutical, a wholly-owned subsidiary of the company, accepted the on-site inspection of cGMP (current good manufacturing practice) from the US food and drug administration (FDA) in April, which included the pre approval inspection of nalmefene hydrochloride injection and nicardipine hydrochloride injection. Recently, Shuode Pharmaceutical received an on-site inspection report issued by the US FDA. FDA confirmed that the inspection was over and Shuode Pharmaceutical passed the on-site inspection. This will help speed up the approval of the company's declared American ANDA products and further accelerate the implementation of the company's internationalization strategy.

Puli Pharmaceuticals: Fluconazole Dry Suspension Approved by FDA

Puli Pharmaceuticals (300630) announced on the evening of September 24 that the company recently received a marketing license for fluconazole dry suspension issued by the US Food and Drug Administration (FDA). Fluconazole dry suspension is indicated for the treatment of oropharyngeal and esophageal candidiasis; candidal urinary tract infections, peritonitis, and systemic candidal infections, including candidemia, disseminated candidiasis, and pneumonia; and cryptococcal meningitis.

Guojin securities: first repurchase of company shares at a cost of about 5 million yuan

Guojin securities (600109) announced on the evening of September 24 that on September 22, the company repurchased the company's shares for the first time by means of centralized bidding transaction, and repurchased 537100 shares for the first time. The highest purchase price was 9.38 yuan/share, and the lowest price was 9.24 yuan/share. The total amount paid was 4.9991 million yuan (excluding stamp duty, commission and other transaction costs).